帕利珠单抗：关于资金投入的一场争论。
Palivizumab: a debate about funding.
作者信息
Fitzgerald Dominic A, Isaacs David, Tobin Bernadette
机构信息
Department of Respiratory Medicine Infectious Diseases, Children's Hospital at Westmead, New South Wales, Australia.
出版信息
J Paediatr Child Health. 2012 May;48(5):373-7. doi: 10.1111/j.1440-1754.2010.01865.x. Epub 2010 Oct 6.
Abstract
A clinician and the chair of the hospital drug committee debate the merits of the use of palivizumab as prophylaxis against respiratory syncytial virus infection for a preterm baby with oxygen-dependent, chronic lung disease and discuss the issue of public funding of palivizumab. An ethicist comments on ethical aspects of the debate about cost-effectiveness.
摘要
一位临床医生与医院药品委员会主席就使用帕利珠单抗预防一名患有依赖氧气的慢性肺病的早产婴儿感染呼吸道合胞病毒的利弊展开辩论，并讨论了帕利珠单抗的公共资金问题。一位伦理学家对关于成本效益的辩论的伦理方面发表了评论。
Zotero 插件